Kuros Biosciences AG Asset Resilience Ratio

Latest as of June 2025: 16.77%

Kuros Biosciences AG asset resilience ratio. Kuros Biosciences AG (KURN) has an Asset Resilience Ratio of 16.77% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Kuros Biosciences AG (KURN) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets

CHF18.44 Million
≈ $23.32 Million USD Cash + Short-term Investments

Total Assets

CHF109.97 Million
≈ $139.03 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of Kuros Biosciences AG (2005–2023)

Asset resilience ratio of Kuros Biosciences AG from 2005 to 2023. This chart shows how Kuros Biosciences AG's Asset Resilience Ratio has changed over time. See Kuros Biosciences AG (KURN) free cash flow to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down Kuros Biosciences AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see KURN current and non-current assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CHF18.44 Million 16.77%
Short-term Investments CHF0.00 0%
Total Liquid Assets CHF18.44 Million 16.77%

Asset Resilience Insights

  • Good Liquidity Position: Kuros Biosciences AG maintains a healthy 16.77% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Kuros Biosciences AG Industry Peers by Asset Resilience Ratio

Compare Kuros Biosciences AG's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
GN Store Nord
CO:GN
Medical Devices -4.56%
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
Medical Devices 6.09%
Polynovo Ltd
AU:PNV
Medical Devices 0.04%
L&C Bio Co. Ltd
KQ:290650
Medical Devices 2.14%
VIROMED MEDICAL NA O.N.
XETRA:VME
Medical Devices 0.03%
Affluent Medical SAS
PA:AFME
Medical Devices 0.03%
DRGEM Corporation
KQ:263690
Medical Devices 2.12%

Kuros Biosciences AG Asset Resilience Ratio by Year (2005–2023)

Kuros Biosciences AG asset resilience ratio by year from 2005 to 2023. The table below shows the annual Asset Resilience Ratio data for Kuros Biosciences AG.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-12-31 0.48% CHF342.00K
≈ $432.38K
CHF71.46 Million
≈ $90.35 Million
-1.52pp
2015-12-31 1.99% CHF65.00K
≈ $82.18K
CHF3.26 Million
≈ $4.12 Million
-10.99pp
2011-12-31 12.98% CHF4.00 Million
≈ $5.06 Million
CHF30.81 Million
≈ $38.96 Million
-1.81pp
2010-12-31 14.80% CHF8.00 Million
≈ $10.11 Million
CHF54.07 Million
≈ $68.36 Million
-39.06pp
2009-12-31 53.86% CHF37.00 Million
≈ $46.78 Million
CHF68.70 Million
≈ $86.86 Million
+16.84pp
2008-12-31 37.02% CHF41.00 Million
≈ $51.84 Million
CHF110.75 Million
≈ $140.02 Million
-16.40pp
2007-12-31 53.42% CHF66.00 Million
≈ $83.44 Million
CHF123.56 Million
≈ $156.21 Million
+22.06pp
2006-12-31 31.35% CHF18.00 Million
≈ $22.76 Million
CHF57.41 Million
≈ $72.58 Million
+30.89pp
2005-12-31 0.46% CHF379.00K
≈ $479.16K
CHF82.39 Million
≈ $104.17 Million
--
pp = percentage points

About Kuros Biosciences AG

SW:KURN Switzerland Medical Devices
Market Cap
$1.04 Billion
CHF818.86 Million CHF
Market Cap Rank
#10047 Global
#130 in Switzerland
Share Price
CHF20.64
Change (1 day)
-0.96%
52-Week Range
CHF16.46 - CHF32.00
All Time High
CHF36.96
About

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; Ma… Read more